IRIS
PIETRA, GABRIELLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 8.390
Totale 8.390
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 8.390
Totale 8.390
Salva come PNG Salva come JPEG
Città #
Genova 6.456
Rapallo 760
Genoa 693
Vado Ligure 476
Bordighera 5
Totale 8.390
Salva come PNG Salva come JPEG
Nome #
Identification of cytomegalovirus (CMV)-specific T lymphocytes displaying an effector-memory phenotype that kill CMV-infected target cells in an HLA-E-restricted fashion 194
Analysis of natural killer cells isolated from human decidua: Evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK-cell function 171
Natural Killer (NK)/melanoma cell interaction induces NK-mediated release of chemotactic High Mobility Group Box-1 (HMGB1) capable of amplifying NK cell recruitment 148
Detection of MAGE-1, -2, and -3 messenger RNA in tissue samples derived from lung and mammary tumors. 144
Human natural killer cells: news in the therapy of solid tumors and high-risk leukemias 143
Effect of tumor cells and tumor microenvironment on NK-cell function. 140
Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor 136
Analysis of natural killer cells isolated from human decidua: Evidence that 2B4 (CD244) functions as an inhibitory receptor and blocks NK cell function 132
Detection of oligoclonal T lymphocytes in lymph nodes draining from advanced non-small-cell lung cancer. 130
Cytokines can counteract the inhibitory effect of MEK-i on NK-cell function 130
Human NK Cells: From Surface Receptors to the Therapy of Leukemias and Solid Tumors. 129
Intensified chemotherapy supported by DMSO-free peripheral blood progenitor cells in breast cancer patients. 128
NK-cell editing mediates epithelial-to-mesenchymal transition via phenotypic and proteomic changes in melanoma cell lines 124
Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts 122
Role of major histocompatibility complex class I expression and natural killer-like T cells in the genetic control of endometriosis. 119
Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages 118
Infusion of in vitro expanded tumour-infiltrating lymphocytes and recombinant interleukin-2 in patients with surgically resected lymph node metastases of malignant melanoma: a pilot study. 117
HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes. 115
Natural killer cells lyse autologous herpes simplex virus infected targets using cytolytic mechanisms distributed clonotypically. 114
Comparative analysis of NK- or NK-CTL-mediated lysis of immature or mature autologous dendritic cells 114
Adherent neoplastic cells grown at confluence downregulate HLA class I expression and enhance their susceptibility to lysis mediated by natural killer cells. 114
Structural basis for a major histocompatibility complex class Ib-restricted T cell response 113
How melanoma cells inactivate NK cells 113
The emerging role of HLA-E-restricted CD8+ T lymphocytes in the adaptive immune response to pathogens and tumors. 112
Analysis of the proliferative and phenotypic properties of tumor infiltrating lymphocytes expanded in vitro in the course of the clinical trial of adoptive immunotherapy of metastatic melanoma. 111
Killer cell immunoglobulin-like receptor 3DL1 polymorphism defines distinct hierarchies of HLA class I recognition 110
alpha-Interferon treatment induces quantitative modifications of HLA class I-associated peptides eluted from cultured cancer cell lines 110
NK-CTLs, a novel HLA-E-restricted T-cell subset 109
Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLA-E during active tuberculosis and express type 2 cytokines 109
Purification and HPLC-MS analysis of a naturally processed HCMV-derived peptide isolated from the HEK-293T/HLA-E+/Ul40+ cell transfectants and presented at the cell surface in the context of HLA-E 109
Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells. 109
Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC. 107
HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes 107
HO-1 downregulation favors BRAFV600 melanoma cell death induced by Vemurafenib/PLX4032 and increases NK recognition 107
Natural killer cells kill human melanoma cells with characteristics of cancer stem cells. 106
Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. 103
Human NK cells: From surface receptors to clinical applications 102
Effect of Melanoma-derived Fibroblasts on NK Cell Phenotype and Functions 101
Hypoxia modifies the transcriptome of human NK cells, modulates their immunoregulatory profile, and influences NK cell subset migration 101
Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity. 101
Quantitative flow cytometric analysis of the effects of cetirizine on the expression of ICAM-1/CD54 on primary cultured nasal cells. 100
Peptide-specific recognition of human cytomegalovirus strains controls adaptive natural killer cells 100
Role of NK cells in immunotherapy and virotherapy of solid tumors 99
Killer Ig-Like Receptors (KIRs): Their Role in NK Cell Modulation and Developments Leading to Their Clinical Exploitation 99
Proliferative, phenotypic and functional and molecular characteristics of tumour-infiltrating lymphocytes obtained from unselected patients with malignant melanomas and expanded in vitro in the presence of recombinant interleukin-2 98
Melanoma immunoediting by NK cells. 98
Isolation, Expansion, and Characterization of Natural Killer Cells and Their Precursors as a Tool to Study Cancer Immunosurveillance 97
Influence of Vitamin D in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab 97
Melanoma cells inhibit NK cell functions-response 96
Melanoma cells inhibit natural killer cell function by modulating the expression of activating receptors and cytolytic activity 96
The analysis of the natural killer-like activity of human cytolytic T lymphocytes revealed HLA-E as a novel target for TCR alpha/beta-mediated recognition 95
Human natural killer cells and other innate lymphoid cells in cancer: Friends or foes? 92
Immune Checkpoint Inhibitors: Anti-NKG2A Antibodies on Board 91
Limiting dilution analysis of peripheral blood lymphocytes reacting with non-small-cell lung cancer: functionally heterogeneous effectors efficiently lyse autologous cancer cells. 90
A new mechanism of resistance to NK cell attack in melanoma 89
Morphological, phenotypic and karyotypic characterization of a novel natural-killer-cell target - evidence of involvement of MHC class-I molecules in NK cell recognition. 87
Normal epithelial cells modulating HLA class I surface molecules are susceptible to lysis mediated by CD3(+) and CD3(-) "nonspecific" killer cells. 87
A conserved energetic footprint underpins recognition of Human Leukocyte Antigen-E by two distinct αβ T cell receptors 87
L19-IL2 immunocytokine in combination with the anti-syndecan-1 46F2SIP antibody format: A new targeted treatment approach in an ovarian carcinoma model 87
Human cytolytic T lymphocytes expressing HLA class I-specific inhibitory receptors 83
MELANOMA CELLS INTERFERE WITH THE ACTIVITY OF NK CELLS BY MODULATING THEIR PHENOTYPE AND CYTOTOXIC FUNCTION 80
Dendritic cell maturation is inhibited by apoptotic bodies and promoted by necrotic cells from human melanoma 76
Melanoma cells inhibit natural killer cell function by modulating their phenotype 76
Heterogeneity of the alpha-interferon-mediated overexpression of class-I and class-II major histocompatibility complex molecules in primary cultured cancer cells. 72
In vitro effects of loratadine and its active metabolite an T lymphocytes 69
Hla-E-Restricted Cytolytic T Lymphocytes: Their Role in Cytomegalovirus Infection and Transplantation 69
Characterization of metabolic and molecular response of a human melanoma cell line resistant to PLX4032 69
Natural Killer Cell Effector Mechanisms Against solid tumors and leukemias and their exploitation in immunotherapy 65
EXPRESSION OF KILLER INHIBOTORY RECEPTOR (KIR) CD158B ON RESIDUAL TCRalpha/beta or gamma/delta T CELLS ON B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA (B-CLL) MODULATE THEIR CYTOTOXIC ACTIVITY 64
Peptides with dual binding specificity for HLA-A2 and HLA-E are encoded by alternatively spliced isoforms of the antioxidant enzymes peroxiredoxin 5 63
The engagement of ctla-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and tnf-alpha production. 61
Polymorphism in human cytomegalovirus UL40 impacts on recognition of HLA-E by natural killer cells. 61
Exploiting Human NK Cells in Tumor Therapy 60
The role of peptide in the recognition of HLA-E by cytomegalovirus-specific CD8+T cells 59
Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: a phase I/II pilot trial. Melanoma Istituto Scientifico Tumori Group. 59
RECOGNITION OF HLA-E BY NATURAL KILLER CELLS IS IMPACTED BY VARIATION IN CYTOMEGALOVIRUS UL40 SEQUENCES IN HAEMOPOIETIC STEM CELL TRANSPLANTATION 57
HLA-E and HLA-E-bound peptides: recognition by subsets of NK and T cells. 57
Recognition of the non-classical MHC class I molecule, HLA-E, by the adaptive immune system 56
Phenotipic and Functional Characterization of Human Decidual Natural Killer Cells 56
Inhibitory checkpoints in human natural killer cells: IUPHAR Review 28 56
NK CELL AND TUMOR MICROENVIRONMENT INTERACTIONS IN MELANOMA 55
Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer 52
Human dendritic cells (DCs) efficiently internalize apoptotic bodies from vaccinia virus infected non Hodgkin lymphoma (NHL) cells. 48
Targeted therapies: Friends or foes for patient's NK cell-mediated tumor immune-surveillance? 45
PLX4032 resistance of patient-derived melanoma cells: crucial role of oxidative metabolism 41
Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. 40
Titolo BOOK Chapter: NK cell effector mechanisms against solid tumors and leukemias and their exploitation in immunotherapy. Cancer Immunotherapy Principles and Practice, edited by Lisa H. Butterfield, PhD, Howard L. Kaufman, MD, FACS, and Francesco M. Marincola, MD, FACS, (Volume Editors). 38
Interleukin-15 and cancer: Some solved and many unsolved questions 38
Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting 34
NK cells and ILCs in tumor immunotherapy 32
Vitamin D plasma level can affect nivolumab drug exposure in a cohort of patients with non-small-cell lung cancer 31
HO-1 Limits the Efficacy of Vemurafenib/PLX4032 in BRAFV600E Mutated Melanoma Cells Adapted to Physiological Normoxia or Hypoxia 24
TIGIT Blockade and IL15 in Tumor Immunotherapy: Together is Better 24
Murine models to study human NK cells in human solid tumors 21
Natural killer cell receptors regulate responses of HLA-E-restricted T cells 19
Immune Checkpoint Blockade: A Strategy to Unleash the Potential of Natural Killer Cells in the Anti-Cancer Therapy 19
The roles of different forms of IL-15 in human melanoma progression 14
Human NK cells and cancer 14
Guadecitabine impact on phenotype and function of peripheral blood and hematopoietic stem cell-derived NK: in vitro differentiation and proliferation 5
Totale 8.569
Salva come PNG Salva come JPEG
Categoria #
all - tutte 24.814
article - articoli 24.155
book - libri 233
conference - conferenze 17
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 409
Totale 49.628
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.932 0 0 0 0 241 246 319 171 208 401 266 80
2020/2021744 41 52 96 54 33 69 43 59 84 80 80 53
2021/20221.072 16 81 87 96 47 76 73 261 59 104 47 125
2022/2023918 99 56 13 78 176 168 0 66 155 3 89 15
2023/2024535 30 62 18 84 61 104 21 20 20 17 22 76
2024/2025496 37 121 66 89 183 0 0 0 0 0 0 0
Totale 8.569